P-gp、MRP1、BCRP在晚期NSCLC中的表达及意义  

Expressions of P-glycoprotein, Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein in Advanced Non-small Cell Lung Cancer and Their Significance

作　　者：王慧娟[1] 王启鸣[2] 樊青霞[1] 朱辉[2] 刘涛[2] 郭志强[1] 马智勇[2] 

机构地区：[1]郑州大学第一附属医院,河南郑州450052 [2]河南省肿瘤医院,河南郑州450008

出　　处：《中国肿瘤》2007年第12期1031-1034,共4页China Cancer

基　　金：河南省省属科研院所研究专项基金(0441130401)

摘　　要：[目的]探讨P-gp、MRP1、BCRP在晚期非小细胞肺癌(NSCLC)中的表达,及其与NSCLC患者临床病理特征及化疗效果的关系。[方法]采用免疫组化SP法检测32例晚期NSCLC患者治疗前肿瘤标本中P-gp、MRP1、BCRP的表达。所有患者接受以铂类为主的化疗方案2个周期,分析P-gp、MRP1、BCRP表达情况与患者临床病理特征及化疗效果的关系。[结果]NSCLC肿瘤中P-gp、MRP1和BCRP阳性表达率分别为46.88%、75.00%和46.88%。腺癌中P-gp表达高于鳞癌;MRP1的表达与年龄有关,60岁以上的患者显示了更高的MRP1表达率。BCRP的表达与化疗效果相关,但P-gp和MRP1的表达与疗效无显著性相关。[结论]BCRP可以作为判断晚期NSCLC患者化疗效果的预测因子。[Purpose] To investigate the expression of P-glycoprotein（P-gp）, nlultidrug resistance protein 1 （MRP1） and breast cancer resistance protein （BCRP）, and the relationship of expression level with clinicopathological features and response to chemotherapy in patients with advanced non-small cell lung cancer （NSCLC）. [Methods] P-gp, MRPI and BCRP were detected immunohistoehemieally in 32 cancer samples from untreated patients with advanced NSCLC who subsequently received platinum-based chemotherapy for 2 cycles. The relationship of P-gp, MRP1 and BCRP expressions with chemotherapeutic response and clinicopathological features were studied. [Results] The positive expression rate of P-gp, MRP1 and BCRP in the NSCLC was 46.88%, 75.00% and 46.88% respectively. P-gp expression in adenocarcinoma was significantly higher than that in squamous cell carcinoma. MRPI expression related to age. Higher MRPI expression was found in patients aged over 60. BCRP expression was associated with response to chemotherapy, but no significant associations with P-gp and MRP1 expression. [Conclusion] BCRP may be serve as a predictor for response to chemotherapy in patients with advanced NSCLC.

关 键 词：肺肿瘤 P-糖蛋白 多药耐药相关蛋白 乳腺癌耐药蛋白 免疫组化 

分 类 号：R734.2[医药卫生—肿瘤]